* Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable phar...
Addition increases diversity of Board governance and supports further independent expertise DURHAM...
Additions to executive team strengthen global leadership and position Company for strategic long-te...
Building a leadership team with global and local experience and expertise to enable rapid execution...
Independent lab results demonstrate that the combination therapy retains neutralizing activity agai...
The partnership will accelerate stockpiling, channel distribution and hospital access for the amuba...
Strategic executive hire adds to Company's global leadership team and positions the Company for con...
The Company is working closely with its commercial partners to supply the combination therapy to pa...
Exclusive development and commercialization rights to VIR-3434 in China strengthen Company's leader...
Data are consistent with the results of the global Phase 3 ACTIV-2 trial, demonstrating a favorable...
DURHAM, N.C. and BEIJING, May 25, 2022 /PRNewswire/ -- Brii Biosciences Limited
2022-05-25 08:00
4735
* Studies conducted by independent labs demonstrate the amubarvimab/romlusevimab combination reta...
DURHAM, N.C. and BEIJING, May 7, 2022 /PRNewswire/ -- Brii Biosciences Limited
2022-05-07 09:00
5255
New data demonstrate BRII-835 (VIR-2218) was well tolerated with notable reductions in serum HBsAgo...
DURHAM, N.C. and BEIJING, March 30, 2022 /PRNewswire/ -- Brii Biosciences
Limited
2022-03-30 08:05
2837
– Advancing key programs in HBV, CNS, and HIV – – Received first BLA approval for COVID-19 Treatme...
The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 ta...
DURHAM, N.C. and BEIJING, Jan. 27, 2022 /PRNewswire/ -- Brii Biosciences
2022-01-27 21:00
3571
DURHAM, N.C. and BEIJING, Dec. 27, 2021 /PRNewswire/ -- Brii Biosciences
2021-12-27 18:45
3384
DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ -- Brii Biosciences
2021-12-12 18:50
3846